TPST (Tempest Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


TPST Tempest Therapeutics Inc TPST
32 GF Score
Price $1.12
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics FCF Margin %?

Tempest Therapeutics TPST 32 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates TPST with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 956 Biotechnology companies, Tempest Therapeutics ranks worse than 104602.41% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Tempest Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-7.60 Mil. Tempest Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Tempest Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Tempest Therapeutics's current FCF Yield % is -148.75%.

The historical rank and industry rank for Tempest Therapeutics's FCF Margin % or its related term are showing as below:


TPST's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -85.21
* Ranked among companies with meaningful FCF Margin % only.

Tempest Therapeutics FCF Margin % Related Terms

Tempest Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Tempest Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tempest Therapeutics FCF Margin % Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Tempest Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TPST vs HOWL, INTI, GTBP: FCF Margin % Comparison

For the Biotechnology subindustry, Tempest Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tempest Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Tempest Therapeutics's FCF Margin % falls into.


TPST
32GF Score
Tempest Therapeutics Inc TPST
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Tempest Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-26.82/0
= %

Tempest Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-7.598/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Tempest Therapeutics (TPST) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tempest Therapeutics and its competitors. According to the industry distribution chart, Tempest Therapeutics ranks #999999 out of 956 companies in the Biotechnology industry.
Is Tempest Therapeutics' FCF Margin % too high?
Tempest Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Tempest Therapeutics ranks #999999 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' FCF Margin % compare to HOWL and INTI?
According to the Biotechnology industry distribution chart, Tempest Therapeutics ranks #999999 out of 956 companies for FCF Margin %. This places Tempest Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tempest Therapeutics and its competitors. Tempest Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tempest Therapeutics Business Description

Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score

Get the complete analysis for TPST

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price